Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$33.0 - $60.04 $9.24 Million - $16.8 Million
-280,000 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$56.15 - $73.9 $6.18 Million - $8.13 Million
110,000 Added 64.71%
280,000 $17.2 Million
Q2 2018

Aug 14, 2018

BUY
$47.85 - $70.45 $2.39 Million - $3.52 Million
50,000 Added 41.67%
170,000 $11.5 Million
Q1 2018

May 15, 2018

BUY
$51.15 - $61.0 $6.14 Million - $7.32 Million
120,000 New
120,000 $6.51 Million

Others Institutions Holding AERI

About AERIE PHARMACEUTICALS INC


  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Summit Partners Public Asset Management, LLC Portfolio

Follow Summit Partners Public Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Partners Public Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Partners Public Asset Management, LLC with notifications on news.